Fintel reports that on December 12, 2025, Citizens maintained coverage of Structure Therapeutics Inc. - Depositary Receipt ...

Fintel reports that on December 11, 2025, Jefferies maintained coverage of Structure Therapeutics Inc. - Depositary Receipt ...

Shares of Structure Therapeutics are soaring Monday after the company reported positive topline data from a weight loss drug ...

As of Monday, December 08, Structure Therapeutics Inc.’s GPCR share price has surged by 76.80%, which has investors ...

Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure Therapeutics stock soars 103% as its oral obesity drug aleniglipron shows strong Phase 2b weight-loss results.

Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering. LifeSci Capital and Citizens ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital and ...

Structure Therapeutics (GPCR) announced the pricing of its upsized underwritten public offering, to generate gross proceeds of approximately $650 million. The company's offering was upsized from a ...